GlassScriptPhysician profile
Emily Carter
NPI 1366994261
$3,339.21
in general payments reported to CMS, 2019-2025
30 companies · $93.23 in 2025
The $93.23 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $812 · 2022: $1,034 · 2023: $1,275 · 2024: $125 · 2025: $93.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,493.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $696.65 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Genzyme Corporation | $405.44 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $303.35 | 2022-2023 | Dupixent |
| Csl Behring | $252.85 | 2022-2023 | Haegarda, Hizentra |
| Glaxosmithkline, LLC. | $162.39 | 2021-2023 | Nucala, Arexvy, Trelegy Ellipta |
| Genentech USA, INC. | $152.33 | 2022-2023 | Xolair |
| Blueprint Medicines Corporation | $141.96 | 2023 | Ayvakit |
| Optinose US, INC. | $118.37 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $117.20 | 2021-2023 | Orladeyo |
| Amgen INC. | $101.69 | 2022-2023 | Tezspire |
| Edwards Lifesciences Corporation | $98.53 | 2022-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $97.38 | 2024 | Lumryz |
| Kaleo, INC. | $89.22 | 2021-2022 | |
| Octapharma USA, INC. | $80.50 | 2021-2023 | Cutaquig |
| Alk-Abello, INC | $71.24 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.05 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Medtronic, INC. | $59.15 | 2022-2023 | Cobalt Dr Mri Surescan |
| Pfizer INC. | $52.57 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $48.18 | 2021 | |
| Uswm, LLC | $30.36 | 2021 | |
| Mylan Specialty L.P. | $29.90 | 2021-2023 | Yupelri |
| Novo Nordisk INC | $21.90 | 2025 | Ozempic |
| Phadia US INC. | $20.95 | 2022 | |
| Dynavax Technologies Corporation | $19.95 | 2023 | Heplisav-B |
| Boston Scientific Corporation | $18.50 | 2025 | General - Female Sui |
| Hikma Pharmaceuticals USA | $18.20 | 2023 | Ryaltris |
| Takeda Pharmaceuticals U.S.A., INC. | $17.05 | 2021 | |
| Astellas Pharma US INC | $16.76 | 2025 | Vyloy |
| Sobi, INC | $14.63 | 2025 | |
| Eyevance Pharmaceuticals LLC | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.